Thank you, Jay. In the next few minutes, I'll provide certain details of our financial performance in the third quarter of 2024. I would encourage you to review our Form 8-K containing our press release and non-GAAP measures as well as our quarterly report on 10-Q, both of which were filed earlier this morning with the U.S. Securities and Exchange Commission. As a continued theme, we have historically noted that our individual quarterly performance can be affected by outside factors. These might include timing fluctuations, including seasonal fluctuations, customer shipments and supply chain issues. Any of these could materially impact a particular quarter either positively or negatively. Consequently, we believe it is more appropriate to review our business on a 12-month basis rather than focus on quarterly performance. This approach will help normalize these potential anomalies and offer a better gauge of our strategy's long-term success. So today, while I'll focus most of my comments on the third quarter and year-to-date 2024 results, I will provide some comparisons for the 12-month period ended September 30, 2024, compared with the same period ended September 30, 2023. Net sales for the third quarter of 2024 totaled $31.4 million. This represents a 5.9% decrease in net sales of $33.4 million in the third quarter of 2023. For the nine months ended September 30, 2024, net sales were $99.5 million as compared with $103.3 million in the same prior year period, a decrease of 3.6%. During 2024, we realized headwinds with our industrial customers as a result of softness in this market, which is similar to results published by other contract manufacturers, as well as delayed product launches. In 2024, we've also experienced revenue headwinds from our medical customers as they are aggressively reducing their inventory investments. We have also noted several medical product introductions being pushed out. We continue to see strong revenue growth in our Aerospace and Defense category in the year-to-date period. Further, as Jay noted in his remarks, customers have changed their purchasing patterns and are requesting short lead times with new orders. These factors drove a reduction in customer backlog as of the end of the third quarter of 2024. Third quarter 2024 gross profit totaled $3.8 million or 12.2% of net sales compared with gross profit of $5.3 million or 15.9% of net sales in the same prior year quarter. For the first nine months of 2024, we realized a gross profit of $13.9 million or 14% of net sales as compared with $16.3 million or 15.8% of net sales in the first nine months of '23. The reduction in gross margin percentages in the 2024 period is largely due to lower net sales and resulting in reduced facility utilization, and to a lesser extent, incremental training and other transition costs related to the movement of Blue Earth's production to Bemidji by the end of 2024. As these costs have ongoing benefit to the company, they are not included in our restructuring costs. Operating expenses for the third quarter and the first nine months of 2024 are lower than the prior year periods as a result of lower incentive compensation accruals and expense management, which offsets increased payroll-related costs. Year-to-date 2024, we have incurred $267,000 of restructuring costs related to retention bonuses and other costs associated with the upcoming Blue Earth closure. We estimate that the Blue Earth closure will result in restructuring cash charges of between $650,000 and $750,000 in 2024. We currently do not anticipate any significant noncash asset impairment charges related to this closure. We expect to pay substantially all of these restructuring costs in 2024. Moving to the cash flow statement. For the nine months ended September 30, 2024, net cash used in operating activities totaled $3 million as compared with cash provided of $2.2 million in the same period in '23. While the timing of customer and vendor payments impact operating cash flows for the period, we have purposely increased inventory levels in anticipation of the Blue Earth facility transitioning to Bemidji. As noted in our press release distributed this morning, we used earnings before interest, tax, depreciation and amortization or EBITDA as well as adjusted EBITDA, which does not reflect the restructuring charges we incurred through the third quarter related to our Blue Earth plant closure as key performance indicators to manage our business. While EBITDA and adjusted EBITDA are non-GAAP measures, we believe these provide meaningful information regarding our underlying core business financial performance. In the press release, we have provided a reconciliation of our financial performance determined in accordance with U.S. generally accepted accounting principles and EBITDA as well as adjusted EBITDA. For the quarter ended September 30, 2024, adjusted EBITDA was $143,000 as compared with $1.6 million for the same period in '23. Year-to-date, adjusted EBITDA was $2.7 million as compared with $4.8 million in the first nine months of 2023. The decrease in adjusted EBITDA is a result of lower net sales and related gross profit. Turning to the balance sheet. As of September 30, 2024, cash and equivalents totaled $1.2 million, down from $1.7 million as of December 31, 2023. The fluctuation in cash balances reflects timing of cash receipts, expenditures and line of credit borrowings. We ended the third quarter of 2024 with $5.5 million of borrowing capacity under our line of credit. Accounts receivable as of September 30, 2024 were $16.6 million, down from $19.3 million as of December 31, 2023. This is in line with our strong fourth quarter sales in 2023 and the expected timing of customer payments. Inventories were $22.3 million as of September 30, 2024, as compared with $21.7 million as of December 31, 2023. The increase reflects the buildup of inventory balances in anticipation of completing the movement of Blue Earth production to our Bemidji facility. Our contract asset, which represents revenue earned, but not yet billed to customers increased to $15.1 million as of September 30, 2024, as compared with $14.5 million at the end of '23. This increase reflects the timing of customer shipments. In our press release issued earlier today, we have presented non-GAAP results, including trailing 12-month financial data and EBITDA. For the trailing 12-month period ended September 30, 2024, net sales were $135.6 million as compared with $138.9 million for the same 12-month period ended September 30, 2023. In addition, adjusted EBITDA for the 12 months period ended September 30, 2024 was $5.9 million as compared with $6 million for the 12-month period ended September 30, 2023. As we stated in August, our top financial priorities for 2024 remain unchanged. First, we are extremely focused on continuing to strengthen our balance sheet. Next, we will take further advantage of opportunities to align our operations and infrastructure, as noted in Jay's comments today with market demand that are seen to deliver sustainable long-term growth as well as driving improvements in free cash flow. Coupled with disciplined lean operations, execution, expense management and R&D innovation, we believe Nortech can deliver on our objectives. With that, I will now turn the call back over to Jay for his closing comments. Jay?